About Measles

- International 22q11.2 Foundation
- Measles is a serious respiratory infection caused by a virus
- · Symptoms include:
 - High fever
- Coughing
- Aches and pains
- Red eyes
- Runny nose
- Rash
- · Complications include:
 - Ear infections
 - Deafness
 - Pneumonia
 - Impact to the immune system having to re-learn how to fight bacteria and viruses
 - Swelling of the brain, often resulting in permanent brain damage, in 1 in 1000 people
 - Lung and neurologic problems in 3 in 1000 people
 - Degenerative nervous system disease 7 to 10 years following infection
 - Death
- Measles spreads very easily through coughing and sneezing
 - 9 out of 10 people who meet someone with measles will become infected
 - The measles virus can stay in the air for 2 hours
- Measles is preventable through vaccination (MMR or MMRV)
 - Two doses of the MMR vaccine are ~97% effective at preventing measles
 - One dose of the MMR vaccine is ~93% effective
 - MMR and MMRV vaccines are safe and effective
 - Vaccination schedule

Travelling internationally | Not Travelling

- For individuals who are immune compromised:
 - Four studies confirmed the safety of the MMR vaccine for individuals with 22q11.2DS.
 - Please consider consulting with your healthcare provider if you or your child has not been vaccinated against measles

For additional information about measles please visit:

- Centers for Disease Control and Prevention (CDC) – Measles (Rubeola)
- Canadian Paediatric Society (CPS) <u>Measles</u>

Research reports about the MMR vaccines and 22q11.2DS:

Vacinas Vivas em Crianças com Síndrome de DiGeorge/ Deleção 22q11.2

(Portuguese)

[Live Vaccine in Children with DiGeorge/22q11.2 Deletion Syndrome].

Miranda M, Martins AT, Carvalho S, Serra-Caetano A, Esteves I, Marques JG. Acta Med Port. 2019 Aug 1;32(7-8):514-519. doi: 10.20344/amp.9802.

<u>Live vaccine use and safety in DiGeorge</u> syndrome.

Hofstetter AM, Jakob K, Klein NP, Dekker CL, Edwards KM, Halsey NA, Baxter R, Williams SE, Graham PL 3rd, LaRussa P. Pediatrics. 2014 Apr;133(4):e946-54. doi: 10.1542/peds.2013-0831.

<u>Live viral vaccines in patients with partial</u>
<u>DiGeorge syndrome: clinical experience and</u>
cellular immunity.

Moylett EH, Wasan AN, Noroski LM, Shearer WT.

Clin Immunol. 2004;112(1):106-112. doi: 10.1016/j.clim.2004.02.008

Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Pediatrics. 2003 Oct;112(4):e325. doi: 10.1542/peds.112.4.e325.

Disclaimer: This information is brought to you by the Foundation for educational purposes only. It is not intended to be taken as medical advice. If you have concerns, please talk to your healthcare provider.